Roivant Sciences Stock Rises 16.9% to $24.71
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
Should l Buy ROIV?
Roivant Sciences is up 16.9%, or $3.57 to $24.71.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ROIV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ROIV
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 27.63 USD with a low forecast of 22.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.140
Low
22.00
Averages
27.63
High
33.00
Current: 21.140
Low
22.00
Averages
27.63
High
33.00
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Roivant Sciences Stock Soars on Positive Phase 2 Results for Brepocitinib
- Clinical Trial Success: Roivant Sciences' BEACON study involving 31 patients demonstrated that the 45 mg brepocitinib group achieved a 100% response rate across multiple endpoints, significantly outperforming the placebo group, indicating the drug's potential in treating cutaneous sarcoidosis.
- Significant Improvement Metrics: On the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI-A), patients in the 45 mg group showed a mean improvement of 22.3 points at Week 16 compared to just 0.7 points in the placebo group, with statistical significance observed as early as Week 4, highlighting the drug's rapid efficacy.
- Future Research Plans: Roivant's subsidiary Priovant plans to initiate a Phase 3 clinical trial for brepocitinib in 2026, further validating its effectiveness in treating cutaneous sarcoidosis, marking a critical step in the drug's clinical development.
- Improved Financial Performance: Roivant reported an adjusted loss of 24 cents per share, better than the consensus estimate of 32 cents, with sales around $2 million, indicating financial improvement and a cash reserve of $4.5 billion supporting future profitability.
See More
Top Performing Large-Cap Stocks Last Week
- Lumentum Earnings Beat: Lumentum Holdings Inc. surged 36.02% this week after reporting second-quarter results that exceeded expectations and providing third-quarter guidance above analyst estimates, thereby boosting investor confidence and significantly driving up the stock price.
- Transportation Stocks Rally: Saia, Inc. jumped 23.07% this week, benefiting from declining oil prices, which led to a strong performance across the transportation sector, indicating optimistic market expectations for transportation demand that could enhance future earnings.
- Westlake Stock Increase: Westlake Corporation saw a 19.27% rise in its stock price this week, reflecting positive market sentiment regarding its business outlook, particularly in the context of declining raw material costs that may improve profitability.
- Market Recovery: The strong performance of these stocks indicates a growing investor confidence in economic recovery, especially amid falling oil prices, which could further drive growth in related industries.
See More
Roivant Sciences Q3 2025 Earnings Call Highlights
- Clinical Trial Progress: Roivant reported positive Phase II results for brepocitinib in cutaneous sarcoidosis, with 100% of patients showing a clinically meaningful 10-point improvement, which is expected to drive future commercialization efforts.
- Financial Performance: The company reported R&D expenses of $165 million for the third quarter, with an adjusted non-GAAP net loss of $167 million; however, cash reserves remain strong at $4.5 billion, providing ample funding for future R&D.
- Future Outlook: Management anticipates that 2026 will be a pivotal year, with multiple clinical trials for brepo expected to conclude in the second half of the year, particularly the Phase III study for cutaneous sarcoidosis, potentially opening new market opportunities.
- Legal Risks: Roivant faces a jury trial against Moderna starting on March 9, raising concerns about legal risks that could impact the company's operations and market performance.
See More
U.S. Markets Increased on Friday; Strategy Reached New Heights
U.S. Stock Market Performance: U.S. stock indexes experienced significant gains on Friday, with the overall market climbing by 2.47%.
Individual Index Gains: The S&P 500 index rose by 2.18%, while the Dow Jones Industrial Average saw an increase of 1.97%.
See More
Molina Healthcare Stock Plummets 29% After Earnings Miss
- Unexpected Quarterly Loss: Molina Healthcare reported an unexpected quarterly loss, causing its stock to plummet 29% in a single day, marking the largest drop since 2012 and indicating significant challenges in profitability.
- Weak 2026 Outlook: The company issued a weak earnings outlook for 2026, which may undermine investor confidence and further pressure the stock price, reflecting market concerns about its future growth potential.
- Strong Overall Market Performance: Despite Molina Healthcare's stock decline, the Dow Jones Industrial Average surged nearly 2% on Friday, reaching a new all-time high, indicating a market preference for value stocks that may overshadow individual stock weaknesses.
- Small Caps Outperform: Small caps showed outstanding performance on Friday, with the Russell 2000 index soaring over 3%, suggesting increased investor confidence in smaller companies, contrasting sharply with Molina's performance.
See More
U.S. Stocks Rise, AutoNation Shares Surge
- Market Performance: U.S. stocks traded higher midway through trading, with the S&P 500 gaining approximately 1.6%, the Dow rising 2.01% to 49,891.59, and the NASDAQ climbing 1.84% to 22,954.50, indicating a positive market sentiment and increased investor confidence.
- Sector Dynamics: Information technology shares gained 2.5% on Friday, while communication services stocks fell by 2%, reflecting a preference for tech stocks and concerns over the communication sector, which may impact future performance of related companies.
- AutoNation Earnings: Shares of AutoNation, Inc. (NYSE:AN) surged over 7% after posting fourth-quarter results, reporting adjusted earnings per share of $5.08, a 2% year-over-year increase that beat analyst expectations of $4.85, despite sales of $6.929 billion missing the consensus estimate of $7.200 billion, showcasing the company's resilience in profitability.
- Economic Indicators: The U.S. Manheim Used Vehicle Value Index rose 2.4% month-over-month in January, while the University of Michigan's consumer sentiment index increased by 0.9 points to 57.3, exceeding market estimates of 55, indicating a rebound in consumer confidence that could positively influence future spending.
See More
Roivant Sciences Stock Soars on Positive Phase 2 Results for Brepocitinib
- Clinical Trial Success: Roivant Sciences' BEACON study involving 31 patients demonstrated that the 45 mg brepocitinib group achieved a 100% response rate across multiple endpoints, significantly outperforming the placebo group, indicating the drug's potential in treating cutaneous sarcoidosis.
- Significant Improvement Metrics: On the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI-A), patients in the 45 mg group showed a mean improvement of 22.3 points at Week 16 compared to just 0.7 points in the placebo group, with statistical significance observed as early as Week 4, highlighting the drug's rapid efficacy.
- Future Research Plans: Roivant's subsidiary Priovant plans to initiate a Phase 3 clinical trial for brepocitinib in 2026, further validating its effectiveness in treating cutaneous sarcoidosis, marking a critical step in the drug's clinical development.
- Improved Financial Performance: Roivant reported an adjusted loss of 24 cents per share, better than the consensus estimate of 32 cents, with sales around $2 million, indicating financial improvement and a cash reserve of $4.5 billion supporting future profitability.
See More
Top Performing Large-Cap Stocks Last Week
- Lumentum Earnings Beat: Lumentum Holdings Inc. surged 36.02% this week after reporting second-quarter results that exceeded expectations and providing third-quarter guidance above analyst estimates, thereby boosting investor confidence and significantly driving up the stock price.
- Transportation Stocks Rally: Saia, Inc. jumped 23.07% this week, benefiting from declining oil prices, which led to a strong performance across the transportation sector, indicating optimistic market expectations for transportation demand that could enhance future earnings.
- Westlake Stock Increase: Westlake Corporation saw a 19.27% rise in its stock price this week, reflecting positive market sentiment regarding its business outlook, particularly in the context of declining raw material costs that may improve profitability.
- Market Recovery: The strong performance of these stocks indicates a growing investor confidence in economic recovery, especially amid falling oil prices, which could further drive growth in related industries.
See More
Roivant Sciences Q3 2025 Earnings Call Highlights
- Clinical Trial Progress: Roivant reported positive Phase II results for brepocitinib in cutaneous sarcoidosis, with 100% of patients showing a clinically meaningful 10-point improvement, which is expected to drive future commercialization efforts.
- Financial Performance: The company reported R&D expenses of $165 million for the third quarter, with an adjusted non-GAAP net loss of $167 million; however, cash reserves remain strong at $4.5 billion, providing ample funding for future R&D.
- Future Outlook: Management anticipates that 2026 will be a pivotal year, with multiple clinical trials for brepo expected to conclude in the second half of the year, particularly the Phase III study for cutaneous sarcoidosis, potentially opening new market opportunities.
- Legal Risks: Roivant faces a jury trial against Moderna starting on March 9, raising concerns about legal risks that could impact the company's operations and market performance.
See More
U.S. Markets Increased on Friday; Strategy Reached New Heights
U.S. Stock Market Performance: U.S. stock indexes experienced significant gains on Friday, with the overall market climbing by 2.47%.
Individual Index Gains: The S&P 500 index rose by 2.18%, while the Dow Jones Industrial Average saw an increase of 1.97%.
See More
Molina Healthcare Stock Plummets 29% After Earnings Miss
- Unexpected Quarterly Loss: Molina Healthcare reported an unexpected quarterly loss, causing its stock to plummet 29% in a single day, marking the largest drop since 2012 and indicating significant challenges in profitability.
- Weak 2026 Outlook: The company issued a weak earnings outlook for 2026, which may undermine investor confidence and further pressure the stock price, reflecting market concerns about its future growth potential.
- Strong Overall Market Performance: Despite Molina Healthcare's stock decline, the Dow Jones Industrial Average surged nearly 2% on Friday, reaching a new all-time high, indicating a market preference for value stocks that may overshadow individual stock weaknesses.
- Small Caps Outperform: Small caps showed outstanding performance on Friday, with the Russell 2000 index soaring over 3%, suggesting increased investor confidence in smaller companies, contrasting sharply with Molina's performance.
See More
U.S. Stocks Rise, AutoNation Shares Surge
- Market Performance: U.S. stocks traded higher midway through trading, with the S&P 500 gaining approximately 1.6%, the Dow rising 2.01% to 49,891.59, and the NASDAQ climbing 1.84% to 22,954.50, indicating a positive market sentiment and increased investor confidence.
- Sector Dynamics: Information technology shares gained 2.5% on Friday, while communication services stocks fell by 2%, reflecting a preference for tech stocks and concerns over the communication sector, which may impact future performance of related companies.
- AutoNation Earnings: Shares of AutoNation, Inc. (NYSE:AN) surged over 7% after posting fourth-quarter results, reporting adjusted earnings per share of $5.08, a 2% year-over-year increase that beat analyst expectations of $4.85, despite sales of $6.929 billion missing the consensus estimate of $7.200 billion, showcasing the company's resilience in profitability.
- Economic Indicators: The U.S. Manheim Used Vehicle Value Index rose 2.4% month-over-month in January, while the University of Michigan's consumer sentiment index increased by 0.9 points to 57.3, exceeding market estimates of 55, indicating a rebound in consumer confidence that could positively influence future spending.
See More
